Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269

1.

Design and development of a disease-specific quality of life tool for patients with aplastic anaemia and/or paroxysmal nocturnal haemoglobinuria (QLQ-AA/PNH)-a report on phase III.

Niedeggen C, Singer S, Groth M, Petermann-Meyer A, Röth A, Schrezenmeier H, Höchsmann B, Brümmendorf TH, Panse J.

Ann Hematol. 2019 May 21. doi: 10.1007/s00277-019-03681-3. [Epub ahead of print]

PMID:
31115593
2.

Effects of continuous high-dose G-CSF administration on hematopoietic stem cell mobilization and telomere length in patients with amyotrophic lateral sclerosis - a pilot study.

Iberl S, Meyer AL, Müller G, Peters S, Johannesen S, Kobor I, Beier F, Brümmendorf TH, Hart C, Schelker R, Herr W, Bogdahn U, Grassinger J.

Cytokine. 2019 Aug;120:192-201. doi: 10.1016/j.cyto.2019.05.003. Epub 2019 May 14.

PMID:
31100684
3.

Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia.

Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Crescenzo R, Mamolo C, Reisman A, Hochhaus A, Brümmendorf TH; BFORE Study Investigators.

J Cancer Res Clin Oncol. 2019 Jun;145(6):1589-1599. doi: 10.1007/s00432-019-02894-3. Epub 2019 Apr 15.

PMID:
30989330
4.

Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha.

Schubert C, Allhoff M, Tillmann S, Maié T, Costa IG, Lipka DB, Schemionek M, Feldberg K, Baumeister J, Brümmendorf TH, Chatain N, Koschmieder S.

J Hematol Oncol. 2019 Apr 2;12(1):36. doi: 10.1186/s13045-019-0722-9.

5.

Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML).

Kessler T, Koschmieder S, Schliemann C, Crysandt M, Mikesch JH, von Stillfried S, Stelljes M, Pohlen M, Lenz G, Kirsch A, Vehring K, Wardelmann E, Hartmann W, Bormann E, Gerss J, Brümmendorf TH, Müller-Tidow C, Berdel WE.

Ann Hematol. 2019 Jun;98(6):1393-1401. doi: 10.1007/s00277-019-03651-9. Epub 2019 Mar 21.

PMID:
30903275
6.

Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling.

Kuepper MK, Bütow M, Herrmann O, Ziemons J, Chatain N, Maurer A, Kirschner M, Maié T, Costa IG, Eschweiler J, Koschmieder S, Brümmendorf TH, Müller-Newen G, Schemionek M.

Leukemia. 2019 Mar 6. doi: 10.1038/s41375-019-0427-7. [Epub ahead of print]

PMID:
30842608
7.

Tracking of myeloid malignancies by targeted analysis of successive DNA methylation at neighboring CG dinucleotides.

Eipel M, Božić T, Mies A, Beier F, Jost E, Brümmendorf TH, Platzbecker U, Wagner W.

Haematologica. 2019 Jan 31. pii: haematol.2018.209734. doi: 10.3324/haematol.2018.209734. [Epub ahead of print]

8.

The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy.

Bilich T, Nelde A, Bichmann L, Roerden M, Salih HR, Kowalewski DJ, Schuster H, Tsou CC, Marcu A, Neidert MC, Lübke M, Rieth J, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Bauer J, Märklin M, Peper JK, Klein R, Kohlbacher O, Kanz L, Rammensee HG, Stevanović S, Walz JS.

Blood. 2019 Feb 7;133(6):550-565. doi: 10.1182/blood-2018-07-866830. Epub 2018 Dec 10.

PMID:
30530751
9.

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.

Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, Krause SW, Kolb HJ, Hossfeld DK, Nerl C, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Balleisen L, Goebeler ME, Hänel M, Ho A, Dengler J, Falge C, Möhle R, Kremers S, Kneba M, Stegelmann F, Köhne CH, Lindemann HW, Waller CF, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Schenk M, Brossart P, Wündisch T, Geer T, Bildat S, Schäfer E, Hasford J, Hehlmann R, Pfirrmann M.

Haematologica. 2019 May;104(5):955-962. doi: 10.3324/haematol.2018.206797. Epub 2018 Dec 4.

10.

Characterization of acute myeloid leukemia with del(9q) - Impact of the genes in the minimally deleted region.

Naarmann-de Vries IS, Sackmann Y, Klein F, Ostareck-Lederer A, Ostareck DH, Jost E, Ehninger G, Brümmendorf TH, Marx G, Röllig C, Thiede C, Crysandt M.

Leuk Res. 2019 Jan;76:15-23. doi: 10.1016/j.leukres.2018.11.007. Epub 2018 Nov 17.

PMID:
30476680
11.

JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation.

Czech J, Cordua S, Weinbergerova B, Baumeister J, Crepcia A, Han L, Maié T, Costa IG, Denecke B, Maurer A, Schubert C, Feldberg K, Gezer D, Brümmendorf TH, Müller-Newen G, Mayer J, Racil Z, Kubesova B, Knudsen T, Sørensen AL, Holmström M, Kjær L, Skov V, Larsen TS, Hasselbalch HC, Chatain N, Koschmieder S.

Leukemia. 2019 Apr;33(4):995-1010. doi: 10.1038/s41375-018-0295-6. Epub 2018 Nov 23.

PMID:
30470838
12.

Validity of RECIST Version 1.1 for Response Assessment in Metastatic Cancer: A Prospective, Multireader Study.

Kuhl CK, Alparslan Y, Schmoee J, Sequeira B, Keulers A, Brümmendorf TH, Keil S.

Radiology. 2019 Feb;290(2):349-356. doi: 10.1148/radiol.2018180648. Epub 2018 Nov 6.

PMID:
30398433
13.

Mutant NRAS Q61K is responsible for MAPK pathway activation in the MARIMO cell line and renders these cells independent of the CALR-MPL-JAK2-STAT5 pathway.

Han L, Czech J, Maurer A, Brümmendorf TH, Chatain N, Koschmieder S.

Leukemia. 2018 Sep;32(9):2087-2090. doi: 10.1038/s41375-018-0234-6. Epub 2018 Aug 8. No abstract available.

PMID:
30115971
14.

Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor.

Isfort S, Crysandt M, Gezer D, Koschmieder S, Brümmendorf TH, Wolf D.

Recent Results Cancer Res. 2018;212:87-108. doi: 10.1007/978-3-319-91439-8_4.

PMID:
30069626
15.

Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia.

Bouillon AS, Ventura Ferreira MS, Awad SA, Richter J, Hochhaus A, Kunzmann V, Dengler J, Janssen J, Ossenkoppele G, Westerweel PE, Te Boekhorst PAW, Mahon FX, Hjorth-Hansen H, Isfort S, Fioretos T, Hummel S, Schemionek M, Wilop S, Koschmieder S, Saußele S, Mustjoki S, Beier F, Brümmendorf TH.

Blood Adv. 2018 Jul 10;2(13):1572-1579. doi: 10.1182/bloodadvances.2018017772.

16.

Additional benefits of telomere length (TL) measurements in chronic lymphocytic leukemia.

Kaifie A, Schikowsky C, Vasko T, Kraus T, Brümmendorf TH, Ziegler P.

Leuk Lymphoma. 2019 Feb;60(2):541-543. doi: 10.1080/10428194.2018.1482544. Epub 2018 Jul 3. No abstract available.

PMID:
29966475
17.

Germ line predisposition to myeloid malignancies appearing in adulthood.

Crysandt M, Brings K, Beier F, Thiede C, Brümmendorf TH, Jost E.

Expert Rev Hematol. 2018 Aug;11(8):625-636. doi: 10.1080/17474086.2018.1494566. Epub 2018 Jul 23. Review.

PMID:
29958021
18.

Influence of Telomere Length in Hepatocytes on Liver Regeneration after Partial Hepatectomy in Rats.

Andert A, Alizai HP, Ulmer TF, Heidenhain C, Ziegler P, Brümmendorf TH, Neumann UP, Beier F, Klink CD.

Eur Surg Res. 2018;59(1-2):83-90. doi: 10.1159/000489090. Epub 2018 Jun 8.

PMID:
29886505
19.

Serum of myeloproliferative neoplasms stimulates hematopoietic stem and progenitor cells.

Lubberich RK, Walenda T, Goecke TW, Strathmann K, Isfort S, Brümmendorf TH, Koschmieder S, Wagner W.

PLoS One. 2018 May 31;13(5):e0197233. doi: 10.1371/journal.pone.0197233. eCollection 2018.

20.

CD57 identifies T cells with functional senescence before terminal differentiation and relative telomere shortening in patients with activated PI3 kinase delta syndrome.

Cura Daball P, Ventura Ferreira MS, Ammann S, Klemann C, Lorenz MR, Warthorst U, Leahy TR, Conlon N, Roche J, Soler-Palacín P, Garcia-Prat M, Fuchs I, Fuchs S, Beier F, Brümmendorf TH, Speckmann C, Olbrich P, Neth O, Schwarz K, Ehl S, Rensing-Ehl A.

Immunol Cell Biol. 2018 Nov;96(10):1060-1071. doi: 10.1111/imcb.12169. Epub 2018 Jun 14.

PMID:
29790605
21.

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.

Gambacorti-Passerini C, Cortes JE, Lipton JH, Kantarjian HM, Kim DW, Schafhausen P, Crescenzo R, Bardy-Bouxin N, Shapiro M, Noonan K, Leip E, DeAnnuntis L, Brümmendorf TH, Khoury HJ.

Haematologica. 2018 Aug;103(8):1298-1307. doi: 10.3324/haematol.2017.171249. Epub 2018 May 17.

22.

Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita.

Kirschner M, Maurer A, Wlodarski MW, Ventura Ferreira MS, Bouillon AS, Halfmeyer I, Blau W, Kreuter M, Rosewich M, Corbacioglu S, Beck J, Schwarz M, Bittenbring J, Radsak MP, Wilk CM, Koschmieder S, Begemann M, Kurth I, Schemionek M, Brümmendorf TH, Beier F.

Leukemia. 2018 Aug;32(8):1762-1767. doi: 10.1038/s41375-018-0125-x. Epub 2018 Apr 2.

PMID:
29749397
23.

Bosutinib in chronic myeloid leukemia: patient selection and perspectives.

Isfort S, Brümmendorf TH.

J Blood Med. 2018 Apr 10;9:43-50. doi: 10.2147/JBM.S129821. eCollection 2018. Review.

24.

[Biobanking requirements from the perspective of the clinician : Experiences in hematology and oncology].

Koschmieder S, Brümmendorf TH.

Pathologe. 2018 Jul;39(4):303-307. doi: 10.1007/s00292-018-0434-x. Review. German.

PMID:
29623404
25.

Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial.

Rinaldetti S, Pfirrmann M, Manz K, Guilhot J, Dietz C, Panagiotidis P, Spiess B, Seifarth W, Fabarius A, Müller M, Pagoni M, Dimou M, Dengler J, Waller CF, Brümmendorf TH, Herbst R, Burchert A, Janβen C, Goebeler ME, Jost PJ, Hanzel S, Schafhausen P, Prange-Krex G, Illmer T, Janzen V, Klausmann M, Eckert R, Büschel G, Kiani A, Hofmann WK, Mahon FX, Saussele S.

Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):266-271. doi: 10.1016/j.clml.2018.02.004. Epub 2018 Feb 8.

26.

Presence of TERT Promoter Mutations is a Secondary Event and Associates with Elongated Telomere Length in Myxoid Liposarcomas.

Ferreira MSV, Crysandt M, Braunschweig T, Jost E, Voss B, Bouillon AS, Knuechel R, Brümmendorf TH, Beier F.

Int J Mol Sci. 2018 Feb 18;19(2). pii: E608. doi: 10.3390/ijms19020608.

27.

Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL.

Schrader A, Crispatzu G, Oberbeck S, Mayer P, Pützer S, von Jan J, Vasyutina E, Warner K, Weit N, Pflug N, Braun T, Andersson EI, Yadav B, Riabinska A, Maurer B, Ventura Ferreira MS, Beier F, Altmüller J, Lanasa M, Herling CD, Haferlach T, Stilgenbauer S, Hopfinger G, Peifer M, Brümmendorf TH, Nürnberg P, Elenitoba-Johnson KSJ, Zha S, Hallek M, Moriggl R, Reinhardt HC, Stern MH, Mustjoki S, Newrzela S, Frommolt P, Herling M.

Nat Commun. 2018 Feb 15;9(1):697. doi: 10.1038/s41467-017-02688-6.

28.

Comprehensive characterization of chorionic villi-derived mesenchymal stromal cells from human placenta.

Ventura Ferreira MS, Bienert M, Müller K, Rath B, Goecke T, Opländer C, Braunschweig T, Mela P, Brümmendorf TH, Beier F, Neuss S.

Stem Cell Res Ther. 2018 Feb 5;9(1):28. doi: 10.1186/s13287-017-0757-1.

29.

Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia.

Khoury HJ, Gambacorti-Passerini C, Brümmendorf TH.

Ann Oncol. 2018 Mar 1;29(3):578-587. doi: 10.1093/annonc/mdy019. Review.

30.

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

Schütz C, Inselmann S, Saussele S, Dietz CT, Müller MC, Eigendorff E, Brendel CA, Metzelder SK, Brümmendorf TH, Waller C, Dengler J, Goebeler ME, Herbst R, Freunek G, Hanzel S, Illmer T, Wang Y, Lange T, Finkernagel F, Hehlmann R, Huber M, Neubauer A, Hochhaus A, Guilhot J, Mahon FX, Pfirrmann M, Burchert A.

Leukemia. 2018 Apr;32(4):1054. doi: 10.1038/leu.2017.348. Epub 2018 Jan 30.

PMID:
29381150
31.

[Leukopenia - A Diagnostic Guideline for the Clinical Routine].

Christen D, Brümmendorf TH, Panse J.

Dtsch Med Wochenschr. 2017 Nov;142(23):1744-1749. doi: 10.1055/s-0043-113123. Epub 2017 Nov 16. German.

PMID:
29145679
32.

How to build an allogeneic hematopoietic cell transplant unit in 2016: Proposal for a practical framework.

Crysandt M, Yakoub-Agha I, Reiß P, Theisen S, Silling G, Glatte P, Nelles E, Lemmen S, Brümmendorf TH, Kontny U, Jost E.

Curr Res Transl Med. 2017 Nov;65(4):149-154. doi: 10.1016/j.retram.2017.10.003. Epub 2017 Nov 6.

PMID:
29122584
33.

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.

Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Brümmendorf TH.

J Clin Oncol. 2018 Jan 20;36(3):231-237. doi: 10.1200/JCO.2017.74.7162. Epub 2017 Nov 1.

34.

Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.

Kantarjian HM, Mamolo CM, Gambacorti-Passerini C, Cortes JE, Brümmendorf TH, Su Y, Reisman AL, Shapiro M, Lipton JH.

Cancer. 2018 Feb 1;124(3):587-595. doi: 10.1002/cncr.31082. Epub 2017 Oct 26.

35.

Elimination of different leukaemia subtypes using novel CD89-specific human cytolytic fusion proteins.

Gresch G, Schenke L, Mladenov R, Zwirner S, Cremer C, Niesen J, Grieger E, Brümmendorf T, Jost E, Fischer R, Stockmeyer B, Barth S, Nachreiner T, Stein C.

Br J Haematol. 2018 Oct;183(2):313-317. doi: 10.1111/bjh.14971. Epub 2017 Oct 19. No abstract available.

PMID:
29048126
36.

Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias.

Cortes JE, Gambacorti-Passerini C, Kim DW, Kantarjian HM, Lipton JH, Lahoti A, Talpaz M, Matczak E, Barry E, Leip E, Brümmendorf TH, Khoury HJ.

Clin Lymphoma Myeloma Leuk. 2017 Oct;17(10):684-695.e6. doi: 10.1016/j.clml.2017.06.001. Epub 2017 Jun 17.

37.

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Andersson EI, Pützer S, Yadav B, Dufva O, Khan S, He L, Sellner L, Schrader A, Crispatzu G, Oleś M, Zhang H, Adnan-Awad S, Lagström S, Bellanger D, Mpindi JP, Eldfors S, Pemovska T, Pietarinen P, Lauhio A, Tomska K, Cuesta-Mateos C, Faber E, Koschmieder S, Brümmendorf TH, Kytölä S, Savolainen ER, Siitonen T, Ellonen P, Kallioniemi O, Wennerberg K, Ding W, Stern MH, Huber W, Anders S, Tang J, Aittokallio T, Zenz T, Herling M, Mustjoki S.

Leukemia. 2018 Mar;32(3):774-787. doi: 10.1038/leu.2017.252. Epub 2017 Aug 14.

PMID:
28804127
38.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J.

Leukemia. 2017 Nov;31(11):2398-2406. doi: 10.1038/leu.2017.253. Epub 2017 Aug 14.

39.

Evidence for a pre-existing telomere deficit in non-clonal hematopoietic stem cells in patients with acute myeloid leukemia.

Ventura Ferreira MS, Crysandt M, Ziegler P, Hummel S, Wilop S, Kirschner M, Schemionek M, Jost E, Wagner W, Brümmendorf TH, Beier F.

Ann Hematol. 2017 Sep;96(9):1457-1461. doi: 10.1007/s00277-017-3049-z. Epub 2017 Jul 3.

PMID:
28674830
40.

Perioperative intravenous immunoglobulin treatment in a patient with severe acquired von Willebrand syndrome: case report and review of the literature.

Jennes E, Guggenberger D, Zotz R, Thompson L, Brümmendorf TH, Koschmieder S, Jost E.

Clin Case Rep. 2017 Mar 30;5(5):664-670. doi: 10.1002/ccr3.890. eCollection 2017 May.

41.

The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients.

Schubert C, Chatain N, Braunschweig T, Schemionek M, Feldberg K, Hoffmann M, Dufva O, Mustjoki S, Brümmendorf TH, Koschmieder S.

Oncotarget. 2017 May 23;8(21):34736-34749. doi: 10.18632/oncotarget.16152.

42.

Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.

Braulke F, Schulz X, Germing U, Schuler E, Platzbecker U, Nolte F, Hofmann WK, Giagounidis A, Götze K, Lübbert M, Schlenk RF, Schanz J, Bacher U, Ganser A, Büsche G, Letsch A, Schafhausen P, Bug G, Brümmendorf TH, Haas R, Trümper L, Shirneshan K, Haase D.

Ann Hematol. 2017 Jun;96(6):887-894. doi: 10.1007/s00277-017-2983-0. Epub 2017 Apr 3.

PMID:
28374162
43.

Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.

Giles FJ, Rea D, Rosti G, Cross NCP, Steegmann JL, Griskevicius L, le Coutre P, Coriu D, Petrov L, Ossenkoppele GJ, Mahon FX, Saussele S, Hellmann A, Koskenvesa P, Brümmendorf TH, Gastl G, Castagnetti F, Vincenzi B, Haenig J, Hochhaus A.

J Cancer Res Clin Oncol. 2017 Aug;143(8):1585-1596. doi: 10.1007/s00432-017-2402-x. Epub 2017 Mar 31.

44.

Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia.

Rajala HLM, Missiry ME, Ruusila A, Koskenvesa P, Brümmendorf TH, Gjertsen BT, Janssen J, Lotfi K, Markevärn B, Olsson-Strömberg U, Stenke L, Stentoft J, Richter J, Hjorth-Hansen H, Kreutzman A, Mustjoki S.

J Cancer Res Clin Oncol. 2017 Aug;143(8):1543-1554. doi: 10.1007/s00432-017-2378-6. Epub 2017 Mar 23.

PMID:
28337541
45.

Mtss1(CSC156) mutant mice fail to display efficient Mtss1 protein depletion.

Fahrenkamp D, Herrmann O, Koschmieder S, Brümmendorf TH, Schemionek M.

Leukemia. 2017 Apr;31(4):1017-1019. doi: 10.1038/leu.2017.19. Epub 2017 Feb 7. No abstract available.

PMID:
28167834
46.

A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens.

Backert L, Kowalewski DJ, Walz S, Schuster H, Berlin C, Neidert MC, Schemionek M, Brümmendorf TH, Vucinic V, Niederwieser D, Kanz L, Salih HR, Kohlbacher O, Weisel K, Rammensee HG, Stevanovic S, Walz JS.

Oncotarget. 2017 Jul 4;8(27):43915-43924. doi: 10.18632/oncotarget.14918.

47.

Building a National Framework for Adolescent and Young Adult Hematology and Oncology and Transition from Pediatric to Adult Care: Report of the Inaugural Meeting of the "AjET" Working Group of the German Society for Pediatric Oncology and Hematology.

Escherich G, Bielack S, Maier S, Braungart R, Brümmendorf TH, Freund M, Grosse R, Hoferer A, Kampschulte R, Koch B, Lauten M, Milani V, Ross H, Schilling F, Wöhrle D, Cario H, Dirksen U.

J Adolesc Young Adult Oncol. 2017 Jun;6(2):194-199. doi: 10.1089/jayao.2016.0075. Epub 2016 Dec 16.

PMID:
27983882
48.

Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.

Ben-Batalla I, Erdmann R, Jørgensen H, Mitchell R, Ernst T, von Amsberg G, Schafhausen P, Velthaus JL, Rankin S, Clark RE, Koschmieder S, Schultze A, Mitra S, Vandenberghe P, Brümmendorf TH, Carmeliet P, Hochhaus A, Pantel K, Bokemeyer C, Helgason GV, Holyoake TL, Loges S.

Clin Cancer Res. 2017 May 1;23(9):2289-2300. doi: 10.1158/1078-0432.CCR-16-1930. Epub 2016 Nov 17.

49.

Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II.

Groth M, Singer S, Niedeggen C, Petermann-Meyer A, Röth A, Schrezenmeier H, Höchsmann B, Brümmendorf TH, Panse J.

Ann Hematol. 2017 Feb;96(2):171-181. doi: 10.1007/s00277-016-2867-8. Epub 2016 Nov 11.

50.

[(Pan-)cytopenia as first manifestation of kryptic telomeropathies in adults].

Schmitt K, Beier F, Panse J, Brümmendorf TH.

Dtsch Med Wochenschr. 2016 Oct;141(21):1578-1580. Epub 2016 Oct 17. Review. German.

PMID:
27750347

Supplemental Content

Loading ...
Support Center